Exploratory Clinical Development World Americas 2010 (ECDW)
Venue: Le MÃ©ridien Cambridge-MIT
|Event Date/Time: Oct 19, 2010||End Date/Time: Oct 22, 2010|
|Registration Date: Oct 18, 2010|
|Early Registration Date: Jul 30, 2010|
head on to find much needed solutions for best selection of drug candidates as early as possible.
Clinical development costs are still rising, there is a decreasing success rate for new drug candidate approval and the duration of development is increasing. Pharmaceutical companies are re-evaluating their strategies to revolutionize R&D in order to make more
effective and informed go/no-go decisions as early as possible, in order to reduce attrition rates shortening drug development timescales.
Extensive research carried out with thought leaders in early clinical development has highlighted some key information. These include identifying and developing biomarkers, innovative clinical trial design, healthy vs.
patient populations for early phase studies, identifying POC criteria, dose selection and safety. This conference will address these key issues.
Learn from real life experiences
In the biomarkers session Russell Weiner from
Bristol-Myers Squibb will discuss how to develop a fit for purpose assay and what you need to measure. Zhaosheng Lin from Pfizer will guide you through the challenges and key considerations in the application of biomarkers in clinical development. Whilst Mark Day from Abbott will demonstrate how biomarkers can be used in translation to guide dose selection and enhance benefit risk assessment. Terri Binder from Eisai will
discuss how imaging can aid decision making.
During Exploratory Clinical Development World
Americas you will hear about the tools that companies are implementing in early clinical development to establish proof of concept quicker: Jeffrey Paul from Pfizer will discuss how enriched patient populations can be used. The integration of quantitative knowledge can
help to establish dose selection and Alaa Ahmad from Bristol-Myers Squibb will explain how. Yili Pritchett from Abbott will discuss how to test several compounds for POC in the same study.
Exploratory Clinical Development World Americas
2010 boasts an excellent speaker line up â€“ including GlaxoSmithKline, AstraZeneca, Merck, Bristol- Myers Squibb, Abbott, Genentech, Amgen, Takeda, Eli Lilly, Eisai, Pfizer, Novartis, Gilead and Hoffmann-La Roche. Who better to provide you with a summary of the best current practices to select the most
appropriate candidates in early clinical development?